310 likes | 417 Views
The Mysteries of Assessing Value For Money in HIV Service Delivery Unlocked: Principles , Group Exercises and Examples. Part 2 Excel exercises: Mead Over Senior Fellow Center for Global Development International AIDS Society Kuala Lumpur, Malaysia July 3, 2013. Overview of this session.
E N D
The Mysteries of Assessing Value For Money in HIV Service Delivery Unlocked: Principles, Group Exercises and Examples Part 2 Excel exercises: Mead Over Senior Fellow Center for Global Development International AIDS Society Kuala Lumpur, Malaysia July 3, 2013
Overview of this session • Using Excel to compute cost-benefit and cost-effectiveness numbers • The impact of discounting on the breakeven point for Treatment as Prevention • Revisiting the cost-effectiveness of MC
Please copy a thumb drive onto your computer’s desktop • Verify that your thumb drive looks like this • Copy onto your computer • Pass the thumb drive on to someone else
Drummond's check-list for assessing economic evaluations 1. Well-defined question? 2. A comprehensive description of the competing alternatives given? 3. Was effectiveness established? 4. All costs and consequences for each alternative identified? 5. Costs and consequences measured accurately? 6. Cost and consequences valued credibly? 7. Costs and consequences adjusted for differential timing (discounting)? 8. Incremental analysis of costs and consequences of alternatives? • Allowance for uncertainty? 10. Did the discussion of study results include all issues of concern to users? (Source: (Drummond M et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford. Oxford University Press. 1997 from http://www.nlm.nih.gov/nichsr/edu/healthecon/drummond_list.html)
Using Excel to compute cost-benefit and cost-effectiveness numbers
Let’s build a cost-benefit analysis from the ground up See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: CB Analysis
In CBA, we can compute net benefits each year See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: CB Analysis (2)
For an introduction to discounting in CEA for health see p.155-157 Source: Over, M., Economics for Health Sector Analysis: Concepts and Cases, World Bank, 1993
Discounting future costs and benefits See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: CB Analysis (3)
Experiment with changing the discount rate See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: CB Analysis (4)
An investment “breaks even”when the initial cost is recovered:“The payback period” See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: CB Analysis (5)
How does the discount rate affect the time until an investment breaks even? See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: CB Analysis (6)
As a bridge to CEA, note that CBA could be split into two parts… See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: CB Analysis (7)
As an alternative to the NPV,CBA can present a CB ratio See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: CB Analysis (8)
The cost-benefit ratio changes with the time horizon See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: CB Analysis (9)
CEA calculations look a lot like the computation of a cost-benefit ratio See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: CE Analysis
CE ratio also depends on the time horizon See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: CE Analysis (2)
The impact of discounting on the breakeven point for Treatment as Prevention
Granich et al compare the costs of UTT to the 2010 WHO guidelines: CD4 < 350 See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: GranichBrkevn
With a zero discount rate, by the year 2055, UTT would be cost-saving See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: GranichBrkevn
With a 3% discount rate, by the year 2075, UTT would be cost-saving See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: GranichBrkevn (2)
With a 10% discount rate, UTT would never be cost-saving See: Mead_Over_CBA_CEA_Exercises_KL_2013.xls, Sheet: GranichBrkevn (3)
Inputs on costs and effects Source: Spreadsheet for Kahn JG, Marseille E, Auvert B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med 2006
One of these, the infection rate, is a bit tricky • Define the following variables: • S be the proportion susceptible (i.e. not infected). Here it is given by cell D15 as: • I be the proportion infected. Here it is 1 - S or: • D is the duration of an individual in the infected status: Authors assume this equals: • In a stable equilibrium, I/S = D * Incidence rate • So the cell D16 is making this assumption to derive the incidence rate from the prevalence rate, I. • 0.256/0.744 = 9 * Infection rate
Based on these inputsthe paper calculates the CE ratio Cost per infection averted is only $181
But …. • New evidence on the cost of MC suggests it varies a great deal and in small scale facilities can be as high as $1,000 per circumcision • And Ministry of Finance decision makers are more likely to use a discount rate as high as 10% or 12% in evaluating projects
What if cost is $1000 and r = 10% ? Cost per infection averted goes up to $6,000
Now Michelle we lead a discussion of some other papers www.CGDev.org